Midcareer Investigator Award

$175,476K24FY2016CANIH

Cedars-Sinai Medical Center, West Hollywood CA

Investigators

Linked publications & trials

Paper 35864460 Paper 35486445 Paper 33949711 Paper 33819069 Paper 32833249 Paper 32132043 Paper 31965406 Paper 31615451 Paper 31479563 Paper 31390061 Paper 31377571 Paper 31297315 Paper 31036926 Paper 31034601 Paper 30980026 Paper 30776477 Paper 30701374 Paper 30664736 Paper 30598238 Paper 30427535 Paper 30347135 Paper 30253446 Paper 30177293 Paper 30139875 Paper 29902938 Paper 29795142 Paper 29778349 Paper 29669727 Paper 29663110 Paper 29521009 Paper 29282360 Paper 29212276 Paper 29103966 Paper 29069714 Paper 28994485 Paper 28735016 Paper 28709888 Paper 28654204 Paper 28589550 Paper 28487295 Paper 28408337 Paper 28371163 Paper 28244492 Paper 28130224 Paper 28026865 Paper 27990661 Paper 27779230 Paper 27771128 Paper 27698439 Paper 27692812 Paper 27683213 Paper 27352635 Paper 27318265 Paper 27060053 Paper 26926927 Paper 26809276 Paper 26762961 Paper 26754552 Paper 26653079 Paper 26484853 Paper 26471350 Paper 26458958 Paper 26452418 Paper 26402245 Paper 26353947 Paper 26332663 Paper 26228494 Paper 26171882 Paper 26165192 Paper 26010160 Paper 25847928 Paper 25794458 Paper 25573005 Paper 25520389 Paper 25492369 Paper 25443902 Paper 25417840 Paper 25393271 Paper 25304929 Paper 25261967 Paper 25242554 Paper 25146088 Paper 25139338 Paper 24931061 Paper 24879044 Paper 24588774 Paper 24568894 Paper 24435840 Paper 24418913 Paper 24224130 Paper 24127391 Paper 24100644 Paper 23985577 Paper 23806388 Paper 23755923 Paper 23752858 Paper 23529469 Paper 23219374 Paper 23219353

Abstract

DESCRIPTION (provided by applicant): This Midcareer Investigator Award application seeks support to provide Dr. Freedland with protected time for patient-oriented research (POR) and to act as research mentor for junior faculty and 1 research fellow per year. Dr. Freedland's POR focuses on retrospective cohort studies with a transitioning emphasis on prospective clinical trials aimed at developing new and less toxic treatments to minimize prostate cancer treatment side effects and slow prostate cancer progression. Herein, he proposes a new trial comparing a carbohydrate-restricted diet vs. control for men with PSA recurrence after prostate cancer therapy aiming to slow the rate of PSA rise (lengthen the PSA doubling time), as an indirect measure of slowed prostate cancer growth. Secondary outcomes include weight loss and important prostate cancer biomarkers. Successful completion of this award will advance our understanding of lifestyle and other low toxicity interventions for prostate cancer as well as help educate the next generation of POR investigators.

View original record on NIH RePORTER →